Company / PP&E (Net)
Zenas BioPharma, Inc. PP&E (Net) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$34.0K
FY2025
5-year range
$34.0K / $193.0K
FY2023-FY2025
Trend
-81.6%
vs FY2024
Sector context
#190 of 193
Health Care
What the data says
Among 193 Health Care companies, Zenas BioPharma, Inc. is in the bottom 2% for pp&e (net). Declined from $193,000 to $34,000 over the past 2 years.
Based on SEC 10-K filings.
$34,000 in FY2025.
Declined from $193,000 to $34,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 193This company $34.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, pp&e (net) decreased 81.6% year-over-year.
- Ranks #190 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.0K | -81.6% |
| FY2024 | $185.0K | -4.1% |
| FY2023 | $193.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026